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ABSTRACT
Bloodstream infection (BSI) in febrile patients is associated with high mortality. Clinical and laboratory
variables, such as procalcitonin (PCT), may predict BSI and help decision-making concerning empirical
treatment. This study compared two models for prediction of BSI, and evaluated the role of PCT vs.
clinical variables, collected daily in 300 consecutive febrile inpatients, for 48 h after onset of fever.
Multiple logistic regression (MLR) and classification and regression tree (CART) models were compared
for discriminatory power and diagnostic performance. BSI was present in 17% of cases. MLR identified
the presence of intravascular devices, nadir albumin and thrombocyte counts, and peak temperature,
respiratory rate and leukocyte counts, but not PCT, as independent predictors of BSI. In contrast, a peak
PCT level of >2.45 ng ⁄mL was the principal discriminator in the decision tree based on CART. The latter
was more accurate (94%) than the model based on MLR (72%; p <0.01). Hence, the presence of BSI in
febrile patients is predicted more accurately and by different variables, e.g., PCT, in CART analysis, as
compared with MLR models. This underlines the value of PCT plus CART analysis in the diagnosis of a
febrile patient.
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INTRODUCTION
Fever is a frequent symptom in patients admitted
to medical wards and raises suspicion of sepsis
[1]. Bloodstream infection (BSI) is present in a
minority of cases with new-onset fever in the
hospital [1–3], but early recognition of BSI is
important, since mortality is higher than in
localised infection, and this is especially the case
when initial empirical treatment is inadequate or
delayed [4–6]. Various studies using multiple
logistic regression (MLR) have evaluated clinical
risk-factors and laboratory variables for the pre-
diction of BSI, including the presence of intravas-
cular devices, peak temperature and white cell
counts, and nadir albumin levels [7–14]. In this
respect, the predictive value of procalcitonin
(PCT) as a marker of BSI is still controversial for
conditions such as respiratory tract and pulmon-
ary disease, pancreatitis, and after trauma, burns
and major surgery, partly because of a sensitivity
that is too high and a low specificity for non-viral
microbial infection [15–28]. Few studies have
assessed the predictive value of PCT in relation
to clinical and laboratory variables in MLR mod-
els, with diverse results [29–33].
Classification and regression tree (CART) ana-
lysis provides an alternative approach to MLR
models, and may be more practical for prediction
of BSI [34]. Recently, the use of a prediction
algorithm was evaluated for classification of
febrile patients into three risk groups for BSI,
with sensitivity and specificity of 93% and 67%,
respectively [34]. Decision trees that result from
CART analysis have also been shown to predict,
reasonably accurately, tuberculous meningitis,
outcome following Staphylococcus aureus and
enterococcal bacteraemia, and serious bacterial
infection (bacteraemia and ⁄ or meningitis) in in-
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fants, although the latter application varies in
accuracy [11,35–38].
The current study hypothesised that predictors
of BSI depend on the model used, and that CART
is superior to MLR in this respect. Thus, CART
analysiswas investigated in comparisonwithMLR
for the prediction of BSI in febrile adults admitted
to medical wards, and the role of PCT was
evaluated in comparison with clinical and labora-
tory variables in these models.
PATIENTS AND METHODS
Study design
During a 1-year period, 300 consecutive patients with new-
onset fever (axillary temperature ‡38.0C or rectal temperature
‡38.3C) admitted to the Department of Internal Medicine at
VU University Medical Centre, Amsterdam were included in
the study. Demographical characteristics of the study popula-
tion have been published separately [2,3]. The local ethics
committee approved the study. Informed consent was obtai-
ned from each patient, or from the next of kin, before inclusion.
Exclusion criteria were pregnancy, shock or a life-expectancy
of <24 h. Patients who received treatment with cytokines (e.g.,
interferon-d or interleukin-2) or cytostatic drugs for solid
tumours or malignant haematological disease were excluded.
Demographical variables recorded at inclusion were age,
gender and ethnicity, and factors that predispose to infections
(e.g., the presence of intravascular devices and use of immuno-
suppressive drugs). Clinical variables recorded at inclusion,
and daily thereafter for 2 days, were temperature, respiratory
rate and heart rate. Blood samples were collected for routine
laboratory analyses, including white blood cell count, platelet
count, and haemoglobin, aspartate aminotransferase (ASAT),
alanine aminotransferase, bilirubin, lactate dehydrogenase,
creatinine, lactate and albumin levels. Laboratory variables
were analysed using an SE 9000 analyser (Sysmec, Kolbe,
Japan) and a 747 automatic analyser (Hitachi, Tokyo Japan).
PCT was measured using an immunoluminometric assay
(BRAHMS Diagnostica, Berlin, Germany) with a lower detec-
tion limit of 0.08 ng ⁄mL; the normal upper limit of PCT is
0.5 ng ⁄mL.
Blood cultures were processed in BACTEC 9120 ⁄ 9240
automated blood culture machines (Becton Dickinson, Frank-
lin Lakes, NJ, USA), and this was followed by culture
identification using routine microbiological methods if growth
was positive. Patients were diagnosed as having BSI after
isolation of a known pathogen from the blood culture.
Infection was presumed on the basis of history, physical
examination and imaging techniques performed by attending
physicians not involved in the present study, and was proven
microbiologically when positive results of cultures of local
specimens were returned.
Statistical analysis
Statistical analysis was performed using SPSS v.10.1.0 (SPSS
Inc., Chicago, IL, USA). Comparison among patient groups
was performed with Fisher’s exact test for dichotomous
variables, and the Mann–Whitney U-test for continuous
variables. Among the three determinations of each continuous
clinical and laboratory variable, the peak or nadir values were
selected for further analysis. Univariate analysis was per-
formed for clinical and laboratory variables, and the same
variables were included in forward MLR analysis to obtain a
set of variables, each contributing significantly to prediction of
BSI. The goodness-of-fit of the model was evaluated with the
Hosmer and Lemeshow statistic, with an adequate calibration
indicated by p >0.05. ORs and 95% CIs were calculated from
regression coefficients and standard errors.
CART analysis was performed using the computer program
S-PLUS 2000 Professional v.1 (MathSoft, Seattle, WA USA).
The same variables evaluated by MLR were entered as
potential predictors in CART analysis. The methodology of
CART analysis is based on binary recursive partitioning
[39,40]. The principal idea is to select splits in which the data
in the descendant subsets are less variable with respect to the
classification problem. Thus, each subset should contain as
many as possible cases belonging to a specified outcome (i.e.,
BSI present), and as few as possible to the other outcome (no
BSI). Binary refers to the fact that all decisions involve a parent
node that is broken into two child nodes. Recursive refers to
the fact that each child node can then become a parent node,
and in a repetitive pattern, a decision tree with expanding
branches is created. Splitting rules are developed in a stepwise
fashion by analysing each potential predictor and all possible
cut-off points. The partitioning is repeated until a subgroup
has a similar endpoint for all cases, or the subgroups are too
small for further analysis. The present study used a minimum
node size of five and a group size (the branch of two nodes
together) of at least ten cases; minimum node deviance was set
at 0.010. Cases with missing data were excluded from analysis.
The discriminatory power of the MLR and CART analyses was
evaluated in terms of sensitivity, specificity, positive predictive
value, negative predictive value and accuracy, calculated
according to standard formulae and compared between both
models with the chi-square test. Exact p values are given until
p was <0.01, with p <0.05 denoting statistical significance.
Data were summarised as median (range).
RESULTS
BSI was significantly more frequent among
women than among men (24 vs. 11%; p <0.01).
BSI and non-BSI groups were identical for other
demographical variables, except that gastrointest-
inal and endocrinological diseases were more
common among the BSI group (Table 1). Clinic-
ally presumed infection was microbiologically
proven in 133 cases (44%), with the respiratory
tract (30%) being the most common site of
infection, followed by the urogenital tract (23%),
skin (23%) and the gastrointestinal tract (11%).
Blood cultures were positive in 52 cases (17%).
Escherichia coli and S. aureus were the microor-
ganisms encountered most frequently (Table 2).
The most likely source of BSI was the skin (15
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cases), followed by the gastrointestinal tract (11),
urogenital tract (10), respiratory tract (4), and the
cardiovascular system (4).
Univariate analysis of clinical and laboratory
variables identified nine different factors that were
predictive of BSI (Table 3). The most important
factor was the peak body temperature. Also, nadir
platelet count, nadir albumin, and peak ASAT,
alanine aminotransferase and peak PCT levels
were associated strongly with BSI. A complete set
of data for MLR and CART analysis was available
for 262 cases (87%), including 45 cases of BSI. MLR
identified six factors associated independently
with BSI (Table 4). PCT was not independently
predictive and was excluded from the MLR
analysis (p 0.29). The MLR model predicted the
presence or absence of BSI correctly in 31 ⁄ 45
(69%) and 157 ⁄ 217 (72%) of cases, respectively
(Table 5). A negative prediction using the model
was correct in 157 ⁄ 171 cases (92%).
CART analysis yielded the decision tree depict-
ed in Fig. 1. A peak PCT level of >2.45 ng ⁄mL
was the principal discriminator, followed by
nadir haemoglobin £6.4 mmol ⁄L, peak body tem-
perature ‡39.0C, nadir albumin £18 g ⁄L, peak
Table 1. Demographics of study population in relation to
presence of bloodstream infectiona
No BSI BSI p value
Age (years) 59 (17–97) 64 (21–92) 0.36
Gender (male ⁄ female) 136 ⁄ 112 17 ⁄ 35 <0.01
Karnofsky score (%) 90 (30–100) 80 (40–100) 0.42
Antibiotics before admission 57 (25) 10 (20) 0.51
Underlying diseaseb
Cardiovascular disease 59 (25) 13 (26) 0.99
Respiratory disease 29 (13) 5 (10) 0.59
Gastrointestinal disease 12 (5) 9 (18) <0.01
Urogenital disease 25 (11) 6 (12) 0.84
Malignancy 51 (22) 14 (28) 0.40
Endocrinological disease 46 (20) 17 (33) 0.04
Autoimmune disease 18 (8) 8 (16) 0.10
Dementia or psychiatric disease 10 (5) 0 0.22
Skin disease 11 (5) 2 (4) 0.80
Immunosuppressive drugs 56 (23) 15 (29) 0.35
Recent surgery 30 (12) 4 (7.7) 0.31
BSI, bloodstream infection.
aData are presented as numbers (%) for dichotomous variables and as medians
(range) for continuous variables.
bIncluding more than one disease per patient.
Table 2. Microorganisms isolated from blood cultures
(n = 52)
Microorganism n
Gram-positive bacteria 25
Staphylococcus aureus 9
Coagulase-negative Staphylococcus 7
Streptococcus pneumoniae 5
Viridans streptococci 4
Gram-negative bacteria 24
Escherichia coli 12
Bacteroides vulgatus 3
Non-typhoid Salmonella spp. 2
Pseudomonas aeruginosa 2
Klebsiella pneumoniae 2
Enterobacter cloacae 1
Morganella morganii 1
Fusobacterium spp. 1
Polymicrobial infectiona 3
aPolymicrobial infection includes cases with: Escherichia coli and Staphylococcus
aureus; Enterobacter cloacae and Proteus mirabilis; and Staphylococcus aureus and
Klebsiella oxytoca.
Table 3. Univariate analysis of clinical and laboratory
variables in patients with and without bloodstream infec-
tion (n = 300)a
No BSI
(n = 248)
BSI
(n = 52) p
Clinical risk-factors
Intravascular catheters 9 (3.6) 6 (12) 0.04
Devices ⁄procedures 45 (18) 15 (29) 0.08
Recent surgery 30 (12) 4 (7.7) 0.31
HIV-seropositive 14 (5.6) 1 (1.9) 0.32
Immunosuppressive drugs 56 (23) 15 (29) 0.35
Underlying malignancy 51 (21) 14 (27) 0.40
Vital and laboratory variables
Peak temperature (C) 39.3 (39.2–39.3) 39.6 (39.3–39.7) <0.01
Peak heart rate (beats ⁄min) 106 (104–109) 112 (106–108) 0.08
Peak systolic blood pressure (mm Hg) 128 (125–131) 132 (125–138) 0.24
Peak respiratory rate (breath ⁄min) 29 (28–30) 28 (26–30) 0.62
Peak WBC count (·109 ⁄L) 12.8 (11.7–13.8) 15.5 (12.6–18.4) 0.11
Nadir platelet count (·109 ⁄L) 216 (199–233) 154 (121–187) 0.01
Nadir haemoglobin (mmol ⁄L) 6.6 (6.5–6.8) 6.2 (5.8–6.5) 0.02
Peak bilirubin (lmol ⁄L) 19 (15–23) 36 (14–58) 0.02
Peak ALAT (U ⁄L) 36 (25–47) 52 (14–90) <0.01
Peak ASAT (U ⁄L) 39 (28–51) 70 (10–129) <0.01
Peak LDH (U ⁄L) 415 (345–485) 476 (303–649) 0.22
Peak creatinine (lmol ⁄L) 164 (135–198) 155 (116–191) 0.08
Nadir albumin (g ⁄L) 24.5 (23.8–25.2) 21.6 (19.8–23.4) <0.01
Peak lactate (mmol ⁄L) 2.0 (1.8–2.2) 2.2 (1.9–2.4) 0.06
Peak procalcitonin (ng ⁄mL) 8.1 (1.8–14.4) 37.8 (7.9–67.9) <0.01
BSI, bloodstream infection; HIV, human immunodeficiency virus; WBC, white
blood cell; ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase;
LDH, lactate dehydrogenase.
aData are presented as numbers (%) for dichotomous variables and as medians
(range) for continuous variables.
Table 4. Logistic regression analysis of clinical and labor-
atory variables predicting bloodstream infection in
patients with fever (n = 262)
OR (95% CI) pa
Nadir albumin level 0.90 (0.84–0.97) <0.01
Nadir platelet count (per 10 units) 0.93 (0.90–0.97) <0.01
Peak WBC count (per 10 units) 2.59 (1.34–3.39) <0.01
Intravascular devices 3.7 (1.1–13) 0.04
Peak temperature 1.9 (1.1–3.5) 0.02
Peak respiratory rate 0.95 (0.90–0.99) 0.03
WBC, white blood cell.
aHosmer–Lemeshow chi-square = 1.7; p 0.988.
Table 5. Diagnostic value of models for prediction of
bloodstream infection
MLR analysis CART analysis p
Sensitivity (%) 69 80 0.17
Specificity (%) 72 96 <0.01
Positive predictive value (%) 34 82 <0.01
Negative predictive value (%) 92 96 0.06
Overall accuracy (%) 72 94 <0.01
MLR, multiple logistic regression; CART, classification and regression tree.
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Fig. 1. Decision tree analysis with peak procalcitonin (PCT) as the principal discriminator for prediction of bloodstream
infection (BSI) in patients with fever (n = 262). (a) Branch of the decision tree in cases where peak PCT was ‡2.45 ng ⁄mL.
(b) Branch with peak PCT levels that are lower than the cut-off value. Endpoint boxes include outcome (BSI or No BSI),
probability (Pr) of outcome, and number (n) of cases included in the node during analysis. ASAT, aspartate
aminotransferase; RR, respiratory rate.
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ASAT level ‡36 U ⁄L and peak lactate levels
‡1.6 mmol ⁄L. BSI was absent in all 67 patients
with a PCT level <2.45 ng ⁄mL, a nadir haemoglo-
bin >6.4 mmol ⁄L and a peak ASAT level
<36 U ⁄L. The probability of absence of BSI was
94% if nadir haemoglobin was £6.4 mmol ⁄L and
the peak lactate level was <1.6 mmol ⁄L in
patients with a PCT level <2.45 ng ⁄mL. BSI was
present in ten (83%) of 12 patients with a PCT
level >2.45 ng ⁄mL, a peak temperature ‡39.0C
and a nadir albumin <18 g ⁄L. The probability of
predicted outcome in the decision tree was 100%
in 12 endpoints with a total of 194 cases (74%).
Only 17 cases were misclassified (6.5%,
95% CI 3.5–9.7), resulting in an accuracy of 94%
(Table 4). In 36 ⁄ 45 cases (80%), the presence of
BSI was predicted correctly; positive prediction of
BSI using the model was correct in 82% of cases
(36 ⁄ 44). The absence of BSI was predicted cor-
rectly in 96% of cases (209 ⁄ 217). CART analysis
was significantly more accurate for prediction of
BSI than the MLR model (p < 0.01), but there was
only a trend toward better sensitivity of the CART
model.
DISCUSSION
This study compared two methods for predic-
tion of BSI among febrile hospitalised patients.
The performance of the MLR model was similar
to that of other models described previously
[2,3,7,10,14]. However, CART analysis, and the
resulting decision tree with PCT as the principal
discriminator, predicted BSI more accurately
than the MLR model, to which PCT did not
contribute. Indeed, the CART prediction model
may be more useful at the bedside than predic-
tion models based on MLR [34]. The use of a
decision tree has several advantages over MLR
models [39,40]. First, CART analysis is an
automated method that is relatively easy to
interpret, with a graphical presentation. The
resulting clinical decision rules are easier for
the clinician to understand than are models
based on MLR. Second, CART analysis is inher-
ently non-parametric, so that no assumptions
are made regarding the underlying distribution
of variables. Categorical factors can thus be used
as well as continuous variables. Finally, the
workflow of a decision tree could be translated
easily into a computer program for automated
calculation.
PCT was the primary discriminator for BSI in
the decision tree, but was not associated inde-
pendently with BSI in MLR analysis. An elevated
PCT level of >2.45 ng ⁄mL was able to stratify
patients into high- and low-risk groups for BSI.
Thus, PCT appeared to be the most important
predictor of BSI in comparison with all the other
clinical risk-factors and laboratory variables
included in the study, which is a finding that
has only been reported previously in patients
attending an emergency department [29]. How-
ever, it has been shown previously that the value
of PCT for predicting serious bacterial infection
in infants is similar to that of traditional markers
of infection [33]. Rapid tests for PCT that allow
bedside determinations of PCT levels are avail-
able, which enhances the clinical applicability of
the decision tree considerably. Based on the
stratification of patients according to PCT and
other clinical variables in the decision tree, rapid
therapeutic interventions will be possible. This
may reduce the use of antibiotics substantially,
as demonstrated recently for PCT-guided treat-
ment of lower respiratory tract infections and
meningitis [26,27].
In addition to the high sensitivity of the
decision tree, the high negative predictive value
of both models is of great importance, as it is
equally relevant to rule out bacteraemia and to
predict its presence. Based on the decision tree,
antimicrobial therapy would have been initiated
correctly in 82% of cases with predicted bacter-
aemia. However, if decisions had been based
solely on a positive prediction using the MLR
model, 60 patients would have been given anti-
microbial treatment, even though no BSI was
present. Eight patients with BSI would have been
missed with the CART model, in comparison with
14 patients who would have been missed with the
MLR model. This illustrates the greater accuracy
of the CART model as a basis for therapeutic
decisions in comparison with the MLR model.
In addition to PCT, nadir haemoglobin, peak
ASAT and peak lactate levels have a prominent
place in the decision tree, but are also not
included in the MLR model, which demonstrates
the model-dependency of predictors. However,
nadir albumin, peak temperature and nadir
thrombocyte count were predictors for BSI in
both MLR and CART analysis. The importance of
these factors, together with the presence of intra-
vascular devices, identified by MLR, is in agree-
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ment with previous reports [2,3,10,13,34]. The
predictive value of nadir thrombocyte counts
probably results from disseminated intravascular
coagulation associated with BSI, whereas reprior-
itising of acute-phase protein over albumin syn-
thesis in the liver as a consequence of the
liberation of cytokines may result in low nadir
albumin levels [1,41].
The present study has some potential limita-
tions. From a practical perspective, only clinical
and laboratory variables that could be determined
rapidly were included in the study, as the aim was
to design a prediction rule to support bedside
decisions concerning the initiation of antimicrobial
therapy directly after the onset of fever. Further-
more, cut-offs of aminimal five cases per node and
ten per group were used in CART analysis to
improve practicability, but at the cost of accuracy.
Only two choices are possible per branch for each
variable. This improves the clinical use of the tree,
but part of the predictive value may be lost if there
is a linear relationship between a continuous
variable (e.g., white blood cell count) and the
likelihood of the outcome (i.e., BSI). Finally, no
prospective validation of the decision tree was
performed. Nevertheless, a decision tree of clinical
risk-factors and laboratory variables should allow
amore accurate prediction of BSI in febrile patients
than an MLR model, partly because different
variables, e.g., PCT, are used. Based on the high
discriminatory power of PCT in the decision tree,
routine determination of PCT should be consid-
ered in the diagnosticworkup of the febrile patient.
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